Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (171-180 of 298) with videos related to

Pageof 30
Sort By:
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous diseaseMary E Horner, Amanda K Abramson, Richard B Warren, et al.
Skinmed|November 12, 2005
PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczemaWilliam Abramovits, Clay Cockerell, Lisa C Stevenson, et al.
The Journal of Dermatological Treatment|March 30, 2012
Long-term management of scalp psoriasis: perspectives from the International Psoriasis CouncilKnud Kragballe, Alan Menter, Mark Lebwohl, et al.
Dermatology (Basel, Switzerland)|January 12, 2008
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary K Willian, Alan Menter, et al.
JAMA Dermatology|December 24, 2014
Central obesity and high blood pressure in pediatric patients with atopic dermatitisJonathan I Silverberg, Lauren Becker, Mary Kwasny, et al.
Journal of the American Academy of Dermatology|January 17, 2012
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to knowBruce E Strober, Katherine Armour, Ricardo Romiti, et al.
Archives of Dermatology|January 19, 2005
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasisAlan Menter, Kenneth Gordon, Wayne Carey, et al.
Journal of the American Academy of Dermatology|January 19, 2016
The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associationsVanessa L Pascoe, Andrew Z Fenves, Jay Wofford, et al.
International Journal of Dermatology|July 9, 2002
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasisMark Lebwohl, Daniel Sherer, Ken Washenik, et al.
Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Pageof 30

Showing results (171-180 of 298) with videos related to

Sort By:
Pageof 30
Journal of the American Academy of Dermatology|April 19, 2014
The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous diseaseMary E Horner, Amanda K Abramson, Richard B Warren, et al.
Skinmed|November 12, 2005
PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczemaWilliam Abramovits, Clay Cockerell, Lisa C Stevenson, et al.
The Journal of Dermatological Treatment|March 30, 2012
Long-term management of scalp psoriasis: perspectives from the International Psoriasis CouncilKnud Kragballe, Alan Menter, Mark Lebwohl, et al.
Dermatology (Basel, Switzerland)|January 12, 2008
Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary K Willian, Alan Menter, et al.
JAMA Dermatology|December 24, 2014
Central obesity and high blood pressure in pediatric patients with atopic dermatitisJonathan I Silverberg, Lauren Becker, Mary Kwasny, et al.
Journal of the American Academy of Dermatology|January 17, 2012
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to knowBruce E Strober, Katherine Armour, Ricardo Romiti, et al.
Archives of Dermatology|January 19, 2005
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasisAlan Menter, Kenneth Gordon, Wayne Carey, et al.
Journal of the American Academy of Dermatology|January 19, 2016
The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associationsVanessa L Pascoe, Andrew Z Fenves, Jay Wofford, et al.
International Journal of Dermatology|July 9, 2002
A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasisMark Lebwohl, Daniel Sherer, Ken Washenik, et al.
Archives of Dermatology|February 20, 2008
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.
Pageof 30